Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Menopause - How up-to-date is this topic?
Changes

Version 1.6, revision planned in 2012.

Last revised in January 2008

December 2010 — minor update. Premique® cycle tablets and Premarin® vaginal cream have been discontinued. The prescriptions have been removed. Issued in December 2010.

July 2010 — minor update. Harmogen tablets (estropipate 1.5 mg) have been discontinued. The prescriptions for this product have been removed. Issued in July 2010.

April 2009 — minor update. Estraderm TTS50® patches and EstraCombi® patches are being discontinued during May to July 2009. The prescriptions for these products have been removed. Estraderm TTS25® and Estraderm TTS100® patches will continue to be available. Issued in May 2009.

March 2009 — minor update to the evidence section for antidepressants. Text discussing a sensitivity analysis for antidepressants is now included. Issued in March 2009.

February 2009 — advice from the Medicines and Healthcare products Regularly Agency (MHRA) that tibolone increases the risk of breast cancer recurrence in women with a history of breast cancer has been included. Issued March 2009.

September 2008 — minor correction to Changes section. Issued in September 2008.

March 2008 — minor text update to the basis of the recommendation about possible risks of hormone replacement therapy.

October 2007 to January 2008 — converted from PRODIGY guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.

There have been no major changes to the recommendations for the use of hormone replacement therapy (HRT). New recommendations about alternatives to HRT (e.g. clonidine and antidepressants) have been included.

© NHS Institute for Innovation and Improvement